Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Improving safety reporting from randomised trials.

John P A Ioannidis1, Joseph Lau

  • 1Clinical Trials and Evidence-Based Medicine Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.

Drug Safety
|March 13, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes of serum adhesion molecules and cytokines in post-ERCP pancreatitis: adhesion molecules and cytokines in acute pancreatitis.

Clinical biochemistry·2014
Same author

Non-publication and delayed publication of randomized trials on vaccines: survey.

BMJ (Clinical research ed.)·2014
Same author

Prevention and control of neglected tropical diseases: overview of randomized trials, systematic reviews and meta-analyses.

Bulletin of the World Health Organization·2014
Same author

Errors (my very own) and the fearful uncertainty of numbers.

European journal of clinical investigation·2014
Same author

Authors' reply to Boucher.

BMJ (Clinical research ed.)·2014
Same author

Assessment of osteoarthritis candidate genes in a meta-analysis of nine genome-wide association studies.

Arthritis & rheumatology (Hoboken, N.J.)·2014
Same journal

Implementation Aspects of a Medicines Shortage Policy Tool: Evidence from Australia's Serious Scarcity Substitution Instruments.

Drug safety·2026
Same journal

Availability and Communication of Risk Management Strategies for Pregnancy Category X Medicines across Australian Medicine Information Sources.

Drug safety·2026
Same journal

The Bidirectionality of Lawyer Reporting Bias in Disproportionality Analysis.

Drug safety·2026
Same journal

Safety of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Longitudinal Analysis.

Drug safety·2026
Same journal

Developing a Hierarchical Algorithm to Identify Pregnancies and Determine Gestational Age from Nationwide Linked Health Data in Taiwan.

Drug safety·2026
Same journal

Safety and Effectiveness of Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis: A Systematic Review and Meta-analysis.

Drug safety·2026
See all related articles

Reporting of safety information in clinical trials is often neglected. Standardized reporting of adverse effects and systematic data collection are crucial for improving patient safety insights from randomized controlled trials.

Area of Science:

  • Clinical Trials
  • Patient Safety
  • Pharmacovigilance

Background:

  • Randomized clinical trials (RCTs) are vital for assessing therapeutic options and capturing safety data.
  • Empirical evidence indicates safety reporting in RCTs is often neglected compared to efficacy outcomes.
  • Inadequate reporting of adverse events and toxicity hinders comprehensive safety assessments.

Purpose of the Study:

  • To highlight the critical need for improved safety reporting in randomized clinical trials.
  • To emphasize the importance of systematic data collection and standardized adverse event reporting.
  • To advocate for enhanced safety surveillance and detailed reporting of toxicity in clinical research.

Main Methods:

  • Analysis of 192 randomized trials to assess the reporting of safety information.

Related Experiment Videos

  • Evaluation of the completeness of reporting for reasons of withdrawal due to toxicity.
  • Assessment of the adequacy of reporting for clinical adverse effects and laboratory-determined toxicity.

    • Main Results:

    • Reasons for toxicity-related withdrawals were specified in only 46% of trial reports.
    • Adequate reporting of clinical adverse effects and laboratory toxicity occurred in only 39% and 29% of trials, respectively.
    • Significant deficiencies exist in the reporting of safety data, even with lenient definitions.

    Conclusions:

    • Standardized scales and systematic data collection are essential for robust safety reporting in RCTs.
    • Active surveillance and detailed reporting of adverse events, including severity and withdrawals, are preferable.
    • Improved safety insights can be gained through standardized reporting, electronic publication, and raw data sharing.